BR112018068189A2 - proteínas de ligação induzíveis e métodos de uso - Google Patents

proteínas de ligação induzíveis e métodos de uso

Info

Publication number
BR112018068189A2
BR112018068189A2 BR112018068189A BR112018068189A BR112018068189A2 BR 112018068189 A2 BR112018068189 A2 BR 112018068189A2 BR 112018068189 A BR112018068189 A BR 112018068189A BR 112018068189 A BR112018068189 A BR 112018068189A BR 112018068189 A2 BR112018068189 A2 BR 112018068189A2
Authority
BR
Brazil
Prior art keywords
methods
polypeptide constructs
binding proteins
disclosed
inducible binding
Prior art date
Application number
BR112018068189A
Other languages
English (en)
Inventor
Panchal Anand
Wesche Holger
Guenot Jeanmarie
Evnin Luke
Vinogradova Maia
Baeuerle Patrick
B Dubridge Robert
Original Assignee
Maverick Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maverick Therapeutics Inc filed Critical Maverick Therapeutics Inc
Publication of BR112018068189A2 publication Critical patent/BR112018068189A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

tratam-se de construções polipeptídicas condicionalmente ativadas que compreendem um domínio ativado por protease que se liga a cd3, pelo menos um domínio de extensão de meia-vida e dois ou mais domínios que se ligam a um ou mais antígenos-alvo. proporcionam-se, também, composições farmacêuticas dos mesmos, bem como ácidos nucleicos, vetores de expressão recombinantes e células hospedeiras para produzir tais construções polipeptídicas. revelam-se métodos de uso das construções polipeptídicas divulgadas na prevenção e/ou no tratamento de doenças, condições e distúrbios.
BR112018068189A 2016-03-08 2017-03-08 proteínas de ligação induzíveis e métodos de uso BR112018068189A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305092P 2016-03-08 2016-03-08
PCT/US2017/021435 WO2017156178A1 (en) 2016-03-08 2017-03-08 Inducible binding proteins and methods of use

Publications (1)

Publication Number Publication Date
BR112018068189A2 true BR112018068189A2 (pt) 2019-02-05

Family

ID=59789722

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018068189A BR112018068189A2 (pt) 2016-03-08 2017-03-08 proteínas de ligação induzíveis e métodos de uso

Country Status (14)

Country Link
US (1) US20180134789A1 (pt)
EP (1) EP3426689A4 (pt)
JP (3) JP7195927B2 (pt)
KR (2) KR102501921B1 (pt)
CN (1) CN109071667A (pt)
AU (1) AU2017229687A1 (pt)
BR (1) BR112018068189A2 (pt)
CA (1) CA3016165A1 (pt)
IL (1) IL261432B2 (pt)
MA (1) MA43816A (pt)
MX (1) MX2018010824A (pt)
SG (1) SG11201807548SA (pt)
TW (2) TW201808990A (pt)
WO (1) WO2017156178A1 (pt)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101997241B1 (ko) 2015-05-21 2019-07-09 하푼 테라퓨틱스, 인크. 삼중특이성 결합 단백질 및 사용 방법
EP3903818A1 (en) 2015-11-19 2021-11-03 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
JP7042467B2 (ja) 2016-05-20 2022-03-28 ハープーン セラピューティクス，インク． 単鎖可変フラグメントｃｄ３結合タンパク質
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
KR102275008B1 (ko) 2016-11-23 2021-07-13 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
MX2019006045A (es) 2016-11-23 2019-11-11 Harpoon Therapeutics Inc Proteinas triespecificas dirigidas a psma y metodos de uso.
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
WO2018160671A1 (en) * 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Targeted checkpoint inhibitors and methods of use
EP3619234A4 (en) * 2017-05-03 2021-05-26 Harpoon Therapeutics, Inc. COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPIES
EP3621648A4 (en) 2017-05-12 2021-01-20 Harpoon Therapeutics, Inc. TRISPECIFIC PROTEINS MSLN AND METHOD OF USE
US10543271B2 (en) 2017-05-12 2020-01-28 Harpoon Therapeutics, Inc. Mesothelin binding proteins
BR112020004543A2 (pt) 2017-09-08 2020-09-08 Maverick Therapeutics, Inc. proteínas de ligação ativadas condicionalmente restritas
JP2020534811A (ja) 2017-09-08 2020-12-03 マベリック セラピューティクス， インコーポレイテッドＭａｖｅｒｉｃｋ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｆｃ領域を含有する条件的に活性化された結合部分
EP3694871A4 (en) 2017-10-13 2021-11-10 Harpoon Therapeutics, Inc. B-CELL MATURATION ANTIG-BINDING PROTEINS
US11136403B2 (en) 2017-10-13 2021-10-05 Harpoon Therapeutics, Inc. Trispecific proteins and methods of use
CA3080429A1 (en) * 2017-11-01 2019-05-09 Nantbio, Inc. Il8 blocking emt pathway and overcoming cancer stem cells
CN110218253B (zh) * 2018-03-02 2020-12-04 广西医科大学 抗CD3的纳米抗体CD3/Nb14及其制备方法与应用
CN110218256B (zh) * 2018-03-02 2020-12-08 广西医科大学 抗CD3的纳米抗体CD3/Nb29及其制备方法与应用
EP3794038A4 (en) * 2018-05-14 2022-02-16 Harpoon Therapeutics, Inc. BINDING FRACTION FOR CONDITIONAL ACTIVATION OF IMMUNOGLOBULIN MOLECULES
WO2019222294A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
US20210269530A1 (en) * 2018-05-14 2021-09-02 Harpoon Therapeutics, Inc. Conditionally activated binding protein comprising a sterically occluded target binding domain
EP4242238A3 (en) 2018-05-14 2023-12-06 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
WO2019246392A1 (en) * 2018-06-22 2019-12-26 Cugene Inc. Cytokine-based bioactivatable drugs and methods of uses thereof
US20210309756A1 (en) 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins
JP7425049B2 (ja) 2018-09-25 2024-01-30 ハープーン セラピューティクス，インク． Ｄｌｌ３結合タンパク質および使用方法
JP2022523708A (ja) * 2019-01-29 2022-04-26 グリットストーン バイオ インコーポレイテッド 多重特異性結合タンパク質
CA3132651A1 (en) 2019-03-05 2020-09-10 Takeda Pharmaceutical Limited Company Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
WO2021097060A1 (en) * 2019-11-13 2021-05-20 Harpoon Therapeutics, Inc. Pro immune modulating molecule comprising a clustering moiety
WO2021121215A1 (en) * 2019-12-20 2021-06-24 Shandong Boan Biotechnology Co., Ltd. Optimized anti-cd3 arm in the generation of t-cell bispecific antibodies for immunotherapy
CN114945597A (zh) * 2020-01-17 2022-08-26 艾提欧生物疗法有限公司 降低脱靶毒性的前抗体
EP4106806A1 (en) 2020-02-21 2022-12-28 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
US20210317188A1 (en) 2020-04-09 2021-10-14 Cytomx Therapeutics, Inc. Compositions containing activatable antibodies
WO2022006562A1 (en) 2020-07-03 2022-01-06 Dana-Farber Cancer Institute, Inc. Multispecific coronavirus antibodies
JP2023538366A (ja) 2020-08-17 2023-09-07 武田薬品工業株式会社 制約され、条件付きで活性化された結合タンパク質
AU2021329330A1 (en) * 2020-08-18 2023-02-02 Onchilles Pharma, Inc. Modified serine protease proproteins
EP4247850A1 (en) 2020-11-20 2023-09-27 Simcere Innovation, Inc. Armed dual car-t compositions and methods for cancer immunotherapy
TW202237654A (zh) 2020-12-09 2022-10-01 美商詹努克斯治療有限公司 與經腫瘤活化之靶定psma及效應細胞抗原之抗體相關之組合物及方法
KR20230165798A (ko) 2021-04-06 2023-12-05 다케다 야쿠힌 고교 가부시키가이샤 제약된 조건부 활성화 결합 단백질을 사용한 치료 방법
WO2022235940A1 (en) 2021-05-06 2022-11-10 Dana-Farber Cancer Institute, Inc. Antibodies against alk and methods of use thereof
WO2023034288A1 (en) 2021-08-31 2023-03-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for treatment of autoimmune disorders and cancer
WO2023097024A1 (en) 2021-11-24 2023-06-01 Dana-Farber Cancer Institute, Inc. Antibodies against ctla-4 and methods of use thereof
WO2023114544A1 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Antibodies and uses thereof
WO2023114543A2 (en) 2021-12-17 2023-06-22 Dana-Farber Cancer Institute, Inc. Platform for antibody discovery
WO2024039670A1 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against cldn4 and methods of use thereof
WO2024039672A2 (en) 2022-08-15 2024-02-22 Dana-Farber Cancer Institute, Inc. Antibodies against msln and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004242846A1 (en) * 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
EP1673398B1 (en) * 2003-10-16 2010-12-29 Micromet AG Multispecific deimmunized cd3-binders
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
EP2609112B1 (en) * 2010-08-24 2017-11-22 Roche Glycart AG Activatable bispecific antibodies
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
SI2714733T1 (sl) * 2011-05-21 2019-06-28 Macrogenics, Inc. CD3-vezavne molekule sposobne vezave na humani ali ne-humani CD3
AU2012280474A1 (en) 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
CN108610421B (zh) 2012-02-27 2022-08-19 阿布林克斯有限公司 Cx3cr1结合多肽
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
WO2013128027A1 (en) 2012-03-01 2013-09-06 Amgen Research (Munich) Gmbh Long life polypeptide binding molecules
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
JP6546160B2 (ja) * 2013-06-10 2019-07-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 腫瘍細胞による免疫抑制を低下させるための方法および組成物
CR20160506A (es) * 2014-03-28 2017-03-10 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3
EP3903818A1 (en) 2015-11-19 2021-11-03 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
US20210309756A1 (en) * 2018-08-09 2021-10-07 Maverick Therapeutics, Inc. Coexpression and purification method of conditionally activated binding proteins

Also Published As

Publication number Publication date
JP2019513014A (ja) 2019-05-23
EP3426689A1 (en) 2019-01-16
TW201808990A (zh) 2018-03-16
KR102501921B1 (ko) 2023-02-21
KR20230041739A (ko) 2023-03-24
CA3016165A1 (en) 2017-09-14
CN109071667A (zh) 2018-12-21
JP2022140856A (ja) 2022-09-28
AU2017229687A1 (en) 2018-09-20
WO2017156178A1 (en) 2017-09-14
TW202302631A (zh) 2023-01-16
RU2018134949A (ru) 2020-04-08
MA43816A (fr) 2018-11-28
IL261432A (en) 2018-10-31
KR20180120245A (ko) 2018-11-05
EP3426689A4 (en) 2020-01-15
SG11201807548SA (en) 2018-09-27
IL261432B2 (en) 2024-03-01
MX2018010824A (es) 2019-05-15
JP2023123519A (ja) 2023-09-05
JP7195927B2 (ja) 2022-12-26
RU2018134949A3 (pt) 2020-08-14
US20180134789A1 (en) 2018-05-17
JP7293456B2 (ja) 2023-06-19
IL261432B1 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
BR112019023856A2 (pt) proteínas triespecíficas que visam msln e métodos de utilização
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
EA202090817A1 (ru) Триспецифические белки и способы их применения
AR105444A1 (es) Anticuerpos terapéuticos que se unen a la proteína codificada por el gen de activación de linfocitos 3 (lag3)
AU2016240220B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
AR115389A1 (es) Anticuerpo antagonista de cd73
PH12019500571A1 (en) Anti-pd-1 antibodies
BR112019004711A2 (pt) receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
EA201792466A1 (ru) АНТИТЕЛА ПРОТИВ FcRn
WO2016063026A3 (en) Selective nav protein binders
BR112018075222A2 (pt) anticorpos anti-tnfrsf25
EA201991181A1 (ru) Psma-нацеленные триспецифические белки и способы их применения
EA201992692A1 (ru) Нацеленные на msln триспецифические белки и способы применения
EA201990927A1 (ru) Антитела против lag-3 и способы их применения

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]